FAGR logo

Fagron NV Stock Price

ENXTBR:FAGR Community·€1.7b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 14 Fair Values set on narratives written by author

FAGR Share Price Performance

€23.80
2.45 (11.48%)
€28.25
Fair Value
€23.80
2.45 (11.48%)
15.8% undervalued intrinsic discount
€28.25
Fair Value
Price €23.80
AnalystConsensusTarget €28.25

FAGR Community Narratives

·
Fair Value €28.25 15.8% undervalued intrinsic discount

APAC Expansion And Compounding Services Will Unlock Future Value

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
€28.25
15.8% undervalued intrinsic discount
Revenue
11.67% p.a.
Profit Margin
10.56%
Future PE
17.67x
Price in 2029
€33.58

Trending Discussion

Updated Narratives

FAGR logo

FAGR: Higher Dividend And Reinforced Outlook Will Support Future Upside

Fair Value: €28.25 15.8% undervalued intrinsic discount
7 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Solid track record and good value.

1 Risk
3 Rewards

Fagron NV Key Details

€952.2m

Revenue

€520.2m

Cost of Revenue

€432.0m

Gross Profit

€341.0m

Other Expenses

€91.0m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Jul 30, 2026
1.24
45.37%
9.56%
74.3%
View Full Analysis

About FAGR

Founded
1990
Employees
4193
CEO
Rafael Padilla
WebsiteView website
www.fagron.com

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort; and Cleoderm, a topical cream used for the compounding of personalized dermatological treatments. It also offers education and professional development of prescribers, hospitals, and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.

Recent FAGR News & Updates

Narrative Update Apr 25

FAGR: Higher Dividend And Reinforced Outlook Will Support Future Upside

Analysts have raised their price target on Fagron to €29 from €28, reflecting updated assumptions that leave fair value, discount rate, revenue growth, profit margin and future P/E broadly unchanged overall. Analyst Commentary Analysts keeping their fair value framework broadly unchanged while lifting the price target to €29 suggests a fine tuning of expectations rather than a major shift in view.

Recent updates

No updates